ChromaGenix, a spinout from North Carolina State University, launched a portfolio of peptide ligands designed to simplify viral vector purification for gene therapy manufacturing. The company is offering peptide-based affinity ligands intended to replace traditional protein ligands in chromatography steps. According to ChromaGenix leadership, the peptides can be produced synthetically at lower cost, are less prone to denaturing into immunogenic fragments, and have a longer usable lifetime in manufacturing. ChromaGenix says it is already selling these ligands to biopharma manufacturers and is working to expand beyond viral vectors, starting with purification of therapeutic cells such as CAR T. The commercialization push matters because affinity chromatography is a bottleneck for scaling viral vector and cell therapy production, and ligand behavior directly affects yield, downstream recovery, and quality risk.